Pages that link to "Q43168171"
Jump to navigation
Jump to search
The following pages link to Phase II study of sunitinib in patients with metastatic urothelial cancer (Q43168171):
Displaying 50 items.
- Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer (Q26744758) (← links)
- Targeted therapy in advanced bladder cancer: what have we learned? (Q27009469) (← links)
- Role of systemic chemotherapy in urothelial urinary bladder cancer (Q27010323) (← links)
- Multimodal management of muscle-invasive bladder cancer (Q27011624) (← links)
- Targeting Hsp90 in urothelial carcinoma (Q27023406) (← links)
- Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma (Q28084715) (← links)
- Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability (Q29012696) (← links)
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer (Q29617772) (← links)
- Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy (Q30563774) (← links)
- Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder (Q30857433) (← links)
- Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75 (Q33394575) (← links)
- A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies (Q33405318) (← links)
- A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer (Q33409364) (← links)
- Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma (Q33411581) (← links)
- PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. (Q33413496) (← links)
- Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer. (Q33431429) (← links)
- Systemic therapy in bladder cancer (Q33578564) (← links)
- Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer (Q33923405) (← links)
- A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials (Q33938637) (← links)
- Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials (Q34094103) (← links)
- Chemotherapy in advanced bladder cancer: current status and future (Q35227771) (← links)
- Personalized therapy for urothelial cancer: review of the clinical evidence (Q36062762) (← links)
- Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma (Q36267685) (← links)
- Novel strategies for treating relapsed/refractory urothelial carcinoma (Q36995686) (← links)
- Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis (Q37108266) (← links)
- Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma (Q37261102) (← links)
- New therapeutic targets in the management of urothelial carcinoma of the bladder (Q37308633) (← links)
- Synergistic effect between cisplatin and sunitinib malate on human urinary bladder-cancer cell lines. (Q37392963) (← links)
- Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention (Q37527255) (← links)
- Serum C-reactive protein level is a significant prognostic indicator in patients with advanced urothelial cancer treated with gemcitabine-cisplatin or carboplatin - preliminary results (Q37579125) (← links)
- Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development. (Q37773367) (← links)
- Angiogenesis as a therapeutic target in urothelial carcinoma (Q37781665) (← links)
- New agents for bladder cancer (Q37799952) (← links)
- Bladder Cancer: Current Management and Opportunities for a Personalized Approach (Q37812062) (← links)
- Vinflunine in the treatment of advanced bladder cancer (Q37821892) (← links)
- Current chemotherapeutic strategies against bladder cancer (Q37888549) (← links)
- Management of advanced bladder cancer in patients with impaired renal function (Q37894683) (← links)
- Current treatment of metastatic bladder cancer and future directions (Q37960909) (← links)
- Urothelial cancers: using biology to improve outcomes (Q37965638) (← links)
- Novel molecular targets for the therapy of urothelial carcinoma (Q38003195) (← links)
- Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. (Q38028124) (← links)
- Novel immunotherapies in GU malignancies (Q38092022) (← links)
- Targeting molecular aberrations in urothelial carcinoma: are we almost there? (Q38110043) (← links)
- Molecular targets on the horizon for kidney and urothelial cancer (Q38132039) (← links)
- Second-line systemic therapy for metastatic urothelial carcinoma of the bladder (Q38155201) (← links)
- Sunitinib malate in the treatment of urothelial cancer (Q38159713) (← links)
- Emerging drugs for urothelial carcinoma (Q38160271) (← links)
- Chemotherapeutic and targeted biological agents for metastatic bladder cancer: a comprehensive review (Q38181169) (← links)
- Targeted therapies in urothelial carcinoma. (Q38200798) (← links)
- Optimal treatment for metastatic bladder cancer (Q38233326) (← links)